Literature DB >> 33718111

Posttranslational Modifications of Smurfs: Emerging Regulation in Cancer.

Longtao Yang1, Wenwen Zhou1, Hui Lin2.   

Abstract

Smad ubiquitination regulatory factors (Smurfs) belong to the Nedd4 subfamily of HECT-type E3 ubiquitin ligases. Under normal situations, Smurfs are exactly managed by upstream regulators, and thereby strictly control tumor biological processes, including cell growth, differentiation, apoptosis, polarization, epithelial mesenchymal transition (EMT), and invasion. Disruption of Smurf activity has been implicated in cancer progression, and Smurf activity is controlled by a series of posttranslational modifications (PTMs), including phosphorylation, ubiquitination, neddylation, sumoylation, and methylation. The effect and function of Smurfs depend on PTMs and regulate biological processes. Specifically, these modifications regulate the functional expression of Smurfs by affecting protein degradation and protein interactions. In this review, we summarize the complexity and diversity of Smurf PTMs from biochemical and biological perspectives and highlight the understanding of their roles in cancer.
Copyright © 2021 Yang, Zhou and Lin.

Entities:  

Keywords:  Smurfs; cancer; phosphorylation; posttranslational modification (PTM); ubiquitination

Year:  2021        PMID: 33718111      PMCID: PMC7950759          DOI: 10.3389/fonc.2020.610663

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  109 in total

1.  CKIP-1 acts as a colonic tumor suppressor by repressing oncogenic Smurf1 synthesis and promoting Smurf1 autodegradation.

Authors:  J Nie; L Liu; G Xing; M Zhang; R Wei; M Guo; X Li; P Xie; L Li; F He; W Han; L Zhang
Journal:  Oncogene       Date:  2016-02-11       Impact factor: 9.867

2.  Detection of protein ubiquitination.

Authors:  Yeun Su Choo; Zhuohua Zhang
Journal:  J Vis Exp       Date:  2009-08-19       Impact factor: 1.355

3.  NEDDylation regulates E2F-1-dependent transcription.

Authors:  Sarah J Loftus; Geng Liu; Simon M Carr; Shonagh Munro; Nicholas B La Thangue
Journal:  EMBO Rep       Date:  2012-07-27       Impact factor: 8.807

4.  REGgamma proteasome mediates degradation of the ubiquitin ligase Smurf1.

Authors:  Jing Nie; Min Wu; Jian Wang; Guichun Xing; Fuchu He; Lingqiang Zhang
Journal:  FEBS Lett       Date:  2010-05-24       Impact factor: 4.124

5.  Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3.

Authors:  Liu-Ya Tang; Motozo Yamashita; Nathan P Coussens; Yi Tang; Xiangchun Wang; Cuiling Li; Chu-Xia Deng; Steven Y Cheng; Ying E Zhang
Journal:  EMBO J       Date:  2011-11-01       Impact factor: 11.598

6.  TRB3 interacts with SMAD3 promoting tumor cell migration and invasion.

Authors:  Fang Hua; Rong Mu; Jinwen Liu; Jianfei Xue; Ziyan Wang; Heng Lin; Hongzhen Yang; Xiaoguang Chen; Zhuowei Hu
Journal:  J Cell Sci       Date:  2011-09-06       Impact factor: 5.285

7.  IRAK2 counterbalances oncogenic Smurf1 in colon cancer cells by dictating ER stress.

Authors:  Jingwen Liu; Yuhan Chen; Qingyang Huang; Wen Liu; Xiqing Ji; Fan Hu; Ying Zhu; Lingqiang Zhang; Guanglong Dong
Journal:  Cell Signal       Date:  2018-05-09       Impact factor: 4.315

Review 8.  A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks.

Authors:  Yu Cao; Lingqiang Zhang
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 9.  The functions and regulation of Smurfs in cancers.

Authors:  Lin Fu; Chun-Ping Cui; Xueli Zhang; Lingqiang Zhang
Journal:  Semin Cancer Biol       Date:  2019-12-30       Impact factor: 15.707

Review 10.  The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.

Authors:  Alan W Lau; Hidefumi Fukushima; Wenyi Wei
Journal:  Front Biosci (Landmark Ed)       Date:  2012-06-01
View more
  1 in total

1.  A ubiquitin-related gene signature for predicting prognosis and constructing molecular subtypes in osteosarcoma.

Authors:  Nan Wei; Gong Chao-Yang; Zhou Wen-Ming; Lei Ze-Yuan; Shi Yong-Qiang; Zhang Shun-Bai; Zhang Kai; Ma Yan-Chao; Zhang Hai-Hong
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.